NanoVibronix, Inc. (NAOV)
NASDAQ: NAOV · Real-Time Price · USD
4.200
-0.780 (-15.66%)
At close: Nov 26, 2025, 4:00 PM EST
4.108
-0.092 (-2.20%)
After-hours: Nov 26, 2025, 7:08 PM EST
NanoVibronix Revenue
NanoVibronix had revenue of $722.00K in the quarter ending September 30, 2025, with 92.02% growth. This brings the company's revenue in the last twelve months to $2.69M, down -18.41% year-over-year. In the year 2024, NanoVibronix had annual revenue of $2.56M with 12.05% growth.
Revenue (ttm)
$2.69M
Revenue Growth
-18.41%
P/S Ratio
0.28
Revenue / Employee
$86,613
Employees
31
Market Cap
4.57M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.56M | 275.00K | 12.05% |
| Dec 31, 2023 | 2.28M | 1.53M | 203.59% |
| Dec 31, 2022 | 752.00K | -943.00K | -55.63% |
| Dec 31, 2021 | 1.70M | 1.07M | 172.07% |
| Dec 31, 2020 | 623.00K | 93.00K | 17.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NAOV News
- 7 days ago - NanoVibronix Issues Letter to Shareholders - Business Wire
- 2 months ago - NanoVibronix Launches “Oscar” Training Aid to Accelerate ENvue Adoption and Unlock New Revenue Opportunities - Business Wire
- 2 months ago - NanoVibronix Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Business Wire
- 2 months ago - NanoVibronix Announces Grant of New U.S. Patent Further Expanding ENvue Medical's Intellectual Property Portfolio - Business Wire
- 2 months ago - NanoVibronix Announces U.S. Patent Granted to ENvue Medical for Real-Time Imaging Overlay in Navigation Technology - Business Wire
- 3 months ago - NanoVibronix Announces Reverse Stock Split - Business Wire
- 4 months ago - NanoVibronix Announces Financing of up to $50 Million Private Placement of Preferred Stock - Business Wire
- 5 months ago - NanoVibronix Announces ENvue Drive – First Intelligent Robotic Platform in Development for Bedside Feeding Tube and Vascular Line Navigation - Business Wire